Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Recruiting 4Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 2Breast 2Sarcoma 1Plasma cell 1Lymphoid 1

Conditions

Ovarian Neoplasms 8Fallopian Tube Neoplasms 7Breast Neoplasms 6Neoplasms 5Triple Negative Breast Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Endometrial Neoplasms 4Neoplasm Metastasis 3Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Xanthogranuloma, Juvenile 1Wilms Tumor 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Prostatic Neoplasms, Castration-Resistant 1Prostate 1Pheochromocytoma 1Peritoneal Neoplasms 1Pathologic Complete Response 1Paraganglioma 1

Interventions

pembrolizumab 17Bevacizumab 12Standard of Care 10Cyclophosphamide 9Carboplatin 9Doxorubicin 7Cetuximab 7Nivolumab 6Exercise 6olaparib 5atezolizumab 5Rituximab 5Radiotherapy 5Pemetrexed 5Fluorouracil 5Cisplatin 5durvalumab 4dostarlimab 4abemaciclib 4Temozolomide 4Prednisone 4Paclitaxel 4Leucovorin 4Blood Specimen Collection 4venetoclax 3temsirolimus 3talazoparib 3pertuzumab 3obinutuzumab 3ibrutinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Neoplasms × olaparib × 30 days × Clear all
NCT07024784 2026-05-19

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

AbbVie

Phase 2 Recruiting
377 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasms

NCT02693535 2026-05-15

TAPUR

American Society of Clinical Oncology

Phase 2 Recruiting
4,200 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT07371104 2026-05-08

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

Daewoong Pharmaceutical Co. LTD.

Phase 1 Recruiting
40 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05933265 2026-05-04

Study of LP-184 in Patients With Advanced Solid Tumors

Lantern Pharma Inc.

Phase 1/2 Active not recruiting
64 enrolled
Breast

Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡